After Apple warned users of implanted medical devices to avoid iPhone 12 and MagSafe accessories, the U.S. Food and Drug Administration weighed in to say that the danger to pacemakers and defibrillators from magnets built into electronic devices is low.
The long-awaited ECG app is almost available on Apple Watch Series 4 (if you live in the U.S.) with watchOS 5.1.2.
It is the first wearable of its kind to offer this functionality, which promises to help uses detect atrial fibrillation — the most common form or irregular rhythm. Irregular heart rhythm notifications have also landed on Series 1 devices and later.
Apple Watch buyers will be granted an extended return period if they decide to return their wearable for reasons related to upcoming heart health features.
Apple usually gives shoppers 14 days to return a purchase, but an internal document reveals that some will have up to 45 days to return a Watch — as long as it’s for the right reasons.
Apple Watch Series 4’s incredible ability to offer electrocardiograms (ECG) is one of the biggest reasons to upgrade this year. But you can’t use it yet.
Those in the U.S. will be able to get their hands on the feature before the end of 2018, but for those in other countries, the wait could be a lot longer. If you live in the U.K., you may even have to wait “years,” one report warns.
One of the Apple Watch Series 4’s massive new features is its electrocardiogram (EKG/ECG) heart rate monitor.
The device is capable of monitoring irregular heart rhythms and reportedly using this to identify potential episodes of atrial fibrillation, a.k.a. AFib. As exciting as the FDA-cleared technology sounds, however, some have expressed their concerns about the tech. A new report cites several concerns — including about Apple’s usual levels of hyperbole.
At yesterday’s iPhone and Apple Watch event, Apple revealed that it has received Food and Drug Administration clearance for the Apple Watch Series 4’s new electrocardiogram feature. In theory, this marks the ascension of the Apple Watch from a wellness health tracker to a full-fledged medical device.
But people shouldn’t be too quick to jump to conclusions about the Apple Watch’s FDA-approval stamp. Adam Masin, a litigator who deals with medical device manufacturers in product liability lawsuits, made a few crucial points on Twitter.
The Food and Drug Administration is making it easier for Apple and other tech companies to get health-related products out to the public faster.
Apple will be part of a new pilot program aimed at rapidly advancing the development of digital health applications. If the program works as intended, it could mean we’ll see new Apple Watch applications and other Apple-made health accessories a lot sooner.
Apple is developing a “killer” new health device that is scheduled to make its debut in 2017, according to a new report. The device will reportedly monitor heart rate and blood sugar, and will somehow be baked into next year’s iPhone.
The Food and Drug Administration is in a tough spot when it comes to health-tracking wearables. As the U.S. government agency in charge of regulating medical devices, it can’t promote health-oriented technology that doesn’t do what it claims, but it also doesn’t want to stifle innovation at a time when Silicon Valley is finally turning its attention to the field.
That’s why, according to a new report, the FDA is giving the tech industry, and particularly tech giants like Apple, leeway to develop new products without aggressive regulation.
While some reports are claiming that Apple is still finalizing the specifications for its first generation iWatch ahead of the supposed October launch, another set of reports — supposedly backed up by insider sources — put forward another theory.
And it makes a lot of sense.
